⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292774 | 0.82 | — | — | |
| SCHEMBL299542 | 0.79 | L3MBTL1 (0.41) | — | |
| SCHEMBL17870561 | 0.76 | PIK3CD (0.48) | — | |
| SCHEMBL27529185 | 0.76 | KDR (0.40) | — | |
| SCHEMBL293672 | 0.73 | — | — | |
| SCHEMBL1581682 | 0.71 | — | — | |
| SCHEMBL19158960 | 0.71 | — | — | |
| SCHEMBL174144 | 0.71 | — | — | |
| SCHEMBL670881 | 0.71 | — | — | |
| SCHEMBL7459363 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113004278-B | Bicyclic heterocycles as FGFR inhibitors | 因赛特控股公司 | 2023-07-21 | — | — | CN | claimed |
| EP-3617205-B1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORP (US) | 2021-08-04 | — | — | EP | claimed |
| CN-113004278-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2021-06-22 | — | — | CN | claimed |
| CN-107438607-B | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2021-02-05 | — | — | CN | claimed |
| EP-3617205-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2020-03-04 | — | — | EP | claimed |
| EP-3259269-B9 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORP (US) | 2020-03-04 | — | — | EP | claimed |
| EP-3259269-B1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORP (US) | 2019-09-04 | — | — | EP | claimed |
| EP-3259269-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2017-12-27 | — | — | EP | claimed |
| US-20170290839-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2017-10-12 | — | — | US | claimed |
| US-9708318-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2017-07-18 | — | — | US | claimed |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL -MEYERS SQUIBB COMPANY | 2009-07-16 | — | — | US | claimed |
| CN-101341129-A | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | CN | claimed |
| CN-101341124-A | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | CN | claimed |
| EP-1981854-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-10-22 | — | — | EP | claimed |
| EP-1966141-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-09-10 | — | — | EP | claimed |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB CO. | 2008-07-03 | — | — | US | claimed |
| WO-2007070818-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070816-A2 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070826-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| US-20070032470-A1 | Novel phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-08 | — | — | US | claimed |